Agree it’s frustrating Winmore (Aka NoVice), but these minor...

Agree it’s frustrating Winmore (Aka NoVice), but these minor fluctuations will be but a distant memory next year.

I was hoping we could get together as a community and put some questions together for the upcoming AGM.
TheRad has been kind enough to carry our questions in the past, I hope he doesn’t mind doing it again this year.

------------------------------------------------

Questions for the AGM.

1. With the Bioterm & Abcam agreements now in place, my understanding is we now have supply chain/mass production capabilities completed. Likewise, the company has stated we can use a generic CPT code for the LDT kit, this means the only remaining step to begin commercialisation in the U.S is a license agreement & KOL engagement/marketing.Has the company set a target date to secure a license agreement and if not, why?

2. Has the company considered applying for breakthrough device application, if not, why?

3. Renalytix has been making great progress in securing contracts with large hospital & insurance networks.With the cost difference aside, does the PIQ management team view KidneyIntelX as a competitor in this space? If not, why?

4. Is Janssen still collaborating in the additional studies there were mentioned from the Ph2 conclusion?

5. What is the price of the PromarkerD test in Italy?

------------------------------------------------

Please add your questions below, based on popularity we can consolidate the list and pick the top few for the AGM.
Hope everyone is having a great weekend!